Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

Dr. Pan got his PhD degree in China Pharmaceutical University. He conducted postdoc research in University of Minnesota, Minnesota, USA. In 2007, he accepted offer from Novartis Institute of Biomedical Research (NIBR). Dr. Pan has worked in NIBR as Research Investigator and Lab Head (the Head of Mechanistic Lab) for four years, focused on drug safety and pharmacokinetics. He is the pioneer of SCH application in Novartis, the leader of Novartis transporter committee.
In 2011, Dr. Pan joined SIMM and started to setup FPA (Formulation Preparation and Bioanalyis) department. He has successfully buildup a high quality bioanalysis center which claimed GLP compliance. The lab has passed OECD inspection in March of 2012, re-inspection in Jan of 2014. It also passed the inspection from MHRA in April of 2013. Meanwhile, Dr. Pan also setup a novel platform for DILI prediction. The platform includes multiple components like drug metabolism and safety assessment, especially from cholestasis perspective. This platform has been successfully used to identify the mechanisms of ANIT liver toxicity and clarify the impacts of type 1 and 2 diabetes on bcrp expression and function. Another application of this platform is to investigate the liver toxicity and DDI of Chinese Herbs. Dr. Pan has clarified the mechanism of hepatotoxicity of Timosaponin A3. Being the future direction of liver toxicity and metabolism studies, Guoyu’s Lab has successfully converted human fibroblasts into hepatocytes-like cells which for the first time showed significant metabolic and biliary excretion capacity, which highlighted the horizon of ADMET studies.

EDUCATION
09/01/2000-06/01/2003 China Pharmaceutical University PhD, Pharmacokinetics
09/01/1997-06/01/2000 China Pharmaceutical University Neuropharmacology Master
09/01/1992-06/01/1997 China Pharmaceutical University Pharmacology BS

WORK EXPERIENCE
03/16/2011-Present SIMM, CDSER, Professor
03/01/2008-03/10/2011 Novartis Institute of Biomedical Research, Lab Head, Investigator
09/01/2007-03/01/2008 Novartis Institute of Biomedical Research, Investigator
01/01/2004-08/30/2007 University of Minnesota, postdoc

Research Directions

1.Drug induced liver injury (DILI) assessment and drug-drug interactions (DDI) predication
2.The development of novel hepatocytes-like cell model (hiHep) and its application in ADMET
3.The distribution and safety of therapeutic cell products in vivo
4.The DDI and liver toxicity of Chinese herbs

Grants & Research Projects

Achievements

1.Established the GLP bioanalysis lab, which could meet the need of drug safety evaluation work. The lab has passed OECD inspection in 2012 and 2014, passed the inspection from MHRA in April, 2013.
2.Established the platform of DILI prediction and assessment, involves in drug metabolism and safety assessment, especially cholestasis.
3.Explained the exacerbated liver toxicity caused by combination treatment with MTX and LEF and may increase the risk of potential drug-drug interactions between PPARaagonists and Mrp substrates in the clinic.

morefold

Social Titles

morefold

Awards & Honors

morefold

Pubilcations

Full Publication List

Selected Publications

(2014- )
1.Wang L, Ma L, Lin Y, Liu X, Xiao L, Zhang Y, Xu Y, Zhou H and Pan G*. Leflunomide increases hepatic exposure to methotrexate and its metabolite by differentially regulating multidrug resistance-associated protein Mrp2/3/4 transporters via peroxisome proliferator-activated receptor alpha activation. Mol Pharmacol. 93:563–574, 2018.
2.Shi X, Gao Y, Yan Y, Ma H, Sun L, Huang P, Ni X, Zhang L, Zhao X, Ren H, Hu D, Zhou Y, Tian F, Ji Y, Cheng X, Pan G*, Ding Y and Hui L. Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes. Cell Res. 26:206-16. 2016.
3.Ni X, Gao Y, Wu Z, Ma L, Chen C, Wang L, Lin Y, Hui L and Pan G*. Functional human induced hepatocytes (hiHeps) with bile acid synthesis and transport capacities: A novel in vitro cholestatic model. Sci Rep. 6:38694. 2016.
4.Wu Z, Yao D, Ji SY, Ni X, Gao Y, Hui L and Pan G*. Optimized hepatocyte-like cells with functional drug transporters directly-reprogrammed from mouse fibroblasts and their potential in drug disposition and toxicology. Cell Physiol Biochem. 38:1815-30. 2016.
5.Ma L, Wu Z, Wang L, Zhang X, Wang J, Chen C, Ni X, Lin Y, Cao Y, Luan Y and Pan G*. Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity. Acta Pharmacol Sin. 37: 1– 10. 2016.
6.Sheng J, Tian X, Xu G, Wu Z, Chen C, Wang L, Pan L, Huang C, Pan G*. The Hepatobiliary disposition of timosaponin B2 is highly dependent on influx/efflux transporters but not metabolism. Drug Metab Dispos. 43(1): 63-72, 2015.
7.Chen C, Wu Z, Ma L, Ni X, Lin Y, Wang L, Chen K, Huang C, Pan G*.Organic anion-transporting polypeptides contribute to the hepatic uptake of berberine. Xenobiotica. 11: 1-9, 2015. 　　
8.Guo C, He L, Yao D, A J, Cao B, Ren J, Wang G, Pan G*. Alpha-naphthylisothiocyanate modulates hepatobiliary transporters in sandwich cultured rat hepatocytes. Toxicol Lett. Volume 224, Issue 1, pp 93-100, 2014. 　　
9.Tian X, Li Z, Lin Y, Chen M, Pan G*, Huang C*. Study on the PK profiles of magnoflorine and its potential interaction in Cortex phellodendri decoction by LC-MS/MS. Anal Bioanal Chem. Volume 406, Issue 3, pp 841-849, 2014. 　　
10.He L, Yang Y, Guo C, Yao D, Liu H, Sheng J, Zhou W, Ren J, Liu X, Pan G*. Opposite regulation of hepatic breast cancer resistance protein in type 1 and 2 diabetes mellitus. Eur J Pharmacol. Volume 724, pp 185-92, 2014. 　

morefold